Skip to main content

Market Overview

Trillium Therapeutics' CD47 Assets Show Continued Anti-Tumor Activity In Hematologic Malignancies

Share:
Trillium Therapeutics' CD47 Assets Show Continued Anti-Tumor Activity In Hematologic Malignancies
  • Trillium Therapeutics Inc (NASDAQ: TRIL) has provided a data update for TTI-622 and 621 programs in hematologic malignancies.
  • As of cut-off data April 12, TTI-622 monotherapy shows a 33% objective response rate (ORR) in relapsed/refractory (R/R) lymphomas at 0.8-18 mg/kg doses, including three new responses (1 Complete Response (CR) + 2 Partial Responses (PRs)) since last data disclosure at the American Society of Hematology 2020 Annual Meeting.
  • TTI-621 monotherapy shows 18-29% ORR in R/R T- and B-cell lymphomas at
  • 0.2-2.0 mg/kg doses, including 3 new responses (1 CR + 2 PRs) in cutaneous T-cell lymphoma (CTCL) since last data disclosure.
  • Both TTI-622 and TTI-621 have been well tolerated at doses up to 18 mg/kg and 2.0 mg/kg weekly, respectively; neither drug candidate reached a maximum tolerated dose level.
  • The company is also initiating Phase 1b/2 programs with TTI-622 and TTI-621 to initially cover seven indications (four hematological cancers, three solid tumors) and study TTI-622 and TTI-621 primarily in combination with other anti-cancer agents.
  • The company has dosed the first multiple myeloma patient in Phase 1a/1b study evaluating the combination of TTI-622 and carfilzomib plus dexamethasone.
  • Trillium expects a robust flow of new data updates and multiple catalysts in 2022.
  • As of March 31, 2021, Trillium had $276 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into 2023.
  • Price Action: TRIL shares are down 0.22% at $9.20 in premarket trading on the last check Wednesday.
 

Related Articles (TRIL)

View Comments and Join the Discussion!

Posted-In: Briefs Hematological MalignanciesBiotech News Health Care Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com